the aurora trial sought to fill this gap the trial was conducted across 280 medical centers in 25 countries the study randomized 2776 patients aged 50 80 years and undergoing maintenance hemodialysis to one of two groups one group received rosuvastatin 10 mg daily and the other group received a placebo the combined primary end point was death from cardiovascular causes nonfatal myocardial infarction or nonfatal stroke although the mean ldl cholesterol was reduced by 43 in the rosuvastatin arm of the study at three months no difference in the primary end point was demonstrated at an average follow up of 3 8 years the trial was sponsored in part by astrazeneca the marketer of crestor